Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis

Scandinavian Journal of Rheumatology

Volumn 39, Issue 1, 2010, Pages 97-98

  Chu Miow Lin, D ^a   Mulleman, D ^a,b,c   Azzopardi, N ^a   Griffoul Espitalier, I ^a   Valat, J P ^a   Paintaud, G ^a   Goupille, P ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b INSERM   (France)

^c SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ANKYLOSING SPONDYLITIS; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LETTER; LONG TERM CARE; MAINTENANCE THERAPY; MALE; PREDICTION; PRIORITY JOURNAL; RISK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LONG-TERM CARE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME;

EID: 76749141805     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903177745     Document Type: Letter

References (7)

1. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;/52:/ 582-91.
2. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;/66:/ 1252-4.
3. Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, et al. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 2009;/61:/569-76.
4. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006;/28:/169-74.
5. Collantes-Estevez E, Muñoz-Villanueva MC, Zarco P, Torre- Alonso JC, Gratacó s J, González C, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. Rheumatology (Oxford) 2005;/44:/ 1555-8.
6. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;/58:/88-97.
7. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, XuW, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008;/48:/681-95.